KRAS and metastatic colorectal cancer: As recently shown in metastatic colorectal cancer treatment, 17% of the KRAS exon 2 wild type patients, who do not respond to anti-EGFR treatment, harbor mutations in KRAS exon 3 and 4 and NRAS exon 2, 3 and 4 [6].